Discordant findings of skeletal metastasis between Tc99m MDP bone scans and F18 FDG PET/CT imaging for advanced breast and lung cancers - Two case reports and literature review

Kaohsiung Journal of Medical Sciences

Volumn 23, Issue 12, 2007, Pages 639-646

  Chen, Yu Wen ^a,b   Huang, Ming Yii ^a,b   Hsieh, Jan Sing ^a,b   Hou, Ming Fung ^a,b   Chou, Shah Hwa ^a,b   Lin, Chih Liang ^c  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c Kaohsiung County Government   (Taiwan)

Author keywords

F18 FDG PET CT; Skeletal metastasis; Tc99m MDP bone scintigraphy

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GEFITINIB; MEDRONATE TECHNETIUM TC 99M;

ADULT; ADVANCED CANCER; ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; BREAST CANCER; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER STAGING; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; FEMALE; FOLLOW UP; FRACTURE; FRACTURE FIXATION; HOSPITAL ADMISSION; HUMAN; LONG BONE; LUNG CANCER; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PELVIS; POSITRON EMISSION TOMOGRAPHY; SPINE;

EID: 38049040736     PISSN: 1607551X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1607-551X(08)70064-0     Document Type: Article

References (13)

1. Paget S. The distribution of secondary growths in cancer of the breast. Lancet 1889;1:571-3.
2. Coleman RE, Rubens RD. The clinical course of bone metastases from breast cancer. Br J Cancer 1987;55:61-6.
3. Roodman GD. Mechanisms of bone metastasis. N Engl J Med 2004;350:1655-64.
4. Coleman RE, Seaman JJ. The role of zoledronic acid in cancer: clinical studies in the treatment and prevention of bone metastases. Semin Oncol 2001;28(Suppl 6):11-6.
5. Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001;27:165-76.
6. Roodman GD. Cell biology of the osteoclast. Exp Hematol 1999;227:1229-41.
7. Yasuda H, Shima N, Nakagawa N, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 1998;95:3597-602.
8. Hofbauer LC, Heufelder AE. Osteoprotegerin and its cognate ligand: a new paradigm of osteoclastogenesis. Eur J Endocrinol 1998:139:152-4.
9. Achbarou A, Kaiser S, Tremblay G, et al. Urokinase overproduction results in increased skeletal metastasis by prostate cancer cells in vivo. Cancer Res 1994;54:2372-7.
10. Roudier MP, Vesselle H, True LD, et al. Bone histology at autopsy and matched bone scintigraphy findings in patients with hormone refractory prostate cancer: the effect of bisphosphonate therapy on bone scintigraphy results. Clin Exp Metastasis 2003;20:171-80.
11. Taube T, Elomaa I, Blomquvist C, et al. Histomorphometric evidence for osteoclast-mediated bone resorption in metastatic breast cancer. Bone 1994;15:161-6.
12. Boyde A, Maconnachie E, Reid SA, et al. Scanning electron microscopy in bone pathology: review of methods, potential and applications. Scan Electron Microsc 1986;4:1537-54.
13. Prevost S, Boucher L, Larivee P, et al. Bone marrow hypermetabolism on FDG PET as survival prognostic factor in non-small-cell lung cancer. JNM 2006;47:559-65.